Takeda Vonola Fumarate Green Tablets Approved for New Indication for Maintenance Treatment of Reflux Esophagitis

Shanghai, October 14, 2021/PRNewswire/ - Takeda China announced today that its innovative acid-suppressing drug, voronola fumarate, has been officially approved by the National Medical Products Administration (NMPA) for use in recurrent cases Maintenance treatment for patients with reflux esophagitis (Reflux Esophagitis, RE)

Reflux esophagitis is a common chronic and progressive disease of the digestive system [1] [2].

Because reflux esophagitis is difficult to cure and easy to relapse, domestic and foreign guidelines have proposed that the treatment standard should always be implemented through the "initial treatment + maintenance treatment" management plan [11] [12] [13] [14] in order to continue to relieve Symptoms, to maintain mucosal healing and reduce the recurrence rate [15] [16] to improve the patient’s health-related quality of life

Vonola fumarate green tablets is the first approved potassium ion competitive acid blocker (P-CAB) [17], which competitively blocks K+ by blocking the K+ channel of H+, K+-ATPase Combined with this enzyme, it can stay in the parietal cells for a long time, thereby quickly inhibiting the secretion of gastric acid.

statement:

1.

2.

[1] Savarino E, et al.

[2] Kawanishi M, et al.

[3] Zou D, et al.

[4] Ram D, et al.

[5] James W, et al.

[6] Pisegna J, et al.

[7] Kong Fanyang, Li Zhaoshen.

[8] Carlsson R, et al.

[9] Yamamoto E, et al.

[10] Lei WY, et al.

[11] Hunt R, et al.
J Clin Gastroenterol.
2017 Jul;51(6):467-478.

[12] Iwakiri K, et al.
J Gastroenterol.
2016 Aug;51(8):751-67.

[13] Digestive Diseases Branch of Chinese Medical Association.
Chinese Journal of Digestion.
2020;40(10):649-663.

[14] Philip O, et al.
Am J Gastroenterol2013;108:308-328.

[15] Hunt R, et al.
J Clin Gastroenterol.
2017;51(6): 467-478

[16] Iwakiri K, et al.
J Gastroenterol.
2016 Aug;51(8):751-67

[17] "39 Health" http://news.
39.
net/a/191220/7704341.
html

[18] Ashida K, et al.
Aliment pHarmacol Ther.
2016;43(2):240-51.

[19] Data on file.
Takeda China analysis Group.
Evidence networks of treatments in reflux esophagitis.

[20] Oshima T, et al.
Aliment pHarmacol Ther.
2019 Jan;49(2):140-146.

[21] Yinglian Xiao et al.
DDW 2020.
Tu1321

Source: Takeda China